There has been a steadily growing armamentarium of drugs for the symptomatic treatment
of Parkinson’s disease (PD). Consequently, as various various pharmaceutical agents are …

Background To compare drug regimens across clinical trials in Parkinson's disease (PD)
conversion formulae between antiparkinsonian drugs have been developed. These are …

Background Objective diagnostic biomarkers are needed to support a clinical diagnosis.
Objectives To analyze markers in various neurodegenerative disorders to identify diagnostic …

Background The objective of this study was to assess neurofilament light chain as a Parkinson's
disease biomarker. Methods We quantified neurofilament light chain in 2 independent …

Background Misfolded α‐synuclein (αSyn) aggregates (αSyn‐seeds) in cerebrospinal fluid (CSF)
are biomarkers for synucleinopathies such as Parkinson's disease (PD). αSyn‐seeds …

D-Cycloserine, known from tuberculosis therapy, has been widely introduced to neuropsychiatric
studies, since its central active mechanism as a partial NMDA-agonist has been found. …

Background Recent studies point toward a significant impact of cardiovascular processes
and inflammation on Parkinson's disease (PD) progression. Objective The aim of this study …

Parkinson’s disease (PD) is the neurological disorder showing the greatest rise in prevalence
from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop …

Purpose: Transcranial direct current stimulation (tDCS) has proven to be a useful tool for
fundamental brain research as well as for attempts in therapy of neurological and psychiatric …

Background The precise clinical diagnosis of Parkinson's disease ( PD ) can be difficult in the
early stages. Diagnostic criteria include the response of key motor features to levodopa as …